Literature DB >> 17416598

Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.

Sandra Cappello1, Tommaso Angelone, Bruno Tota, Pasquale Pagliaro, Claudia Penna, Raffaella Rastaldo, Angelo Corti, Gianni Losano, Maria Carmela Cerra.   

Abstract

The acidic protein chromogranin A (CgA) is the precursor of several regulatory peptides generated by specific proteolytic processes. Human recombinant CgA NH(2)-terminal fragment STA-CgA(1-78) (hrSTA-CgA(1-78)), containing vasostatin-1 (CgA(1-76)) domain, exerts a negative inotropic effect and counteracts the beta-adrenergic positive inotropic effect on the rat heart. We hypothesized an involvement of nitric oxide (NO)-dependent pathway in both cardiodepression and cardioprotection by hrSTA-CgA(1-78). We also hypothesized an involvement of adenosine A(1) receptor and protein kinase C (PKC) in cardioprotection by hrSTA-CgA(1-78). Therefore, we evaluated whether 1) the cardioinhibition mediated by hrSTA-CgA(1-78) involves the G(i/o) proteins/NO-dependent signal transduction cascade, 2) hrSTA-CgA(1-78) induces ischemic preconditioning-like protective effects on the myocardium, and 3) inhibition of NO synthase (NOS), adenosine A(1) receptor, or PKC affects hrSTA-CgA(1-78) protection. Using the isolated rat heart, we found that the reduction of left ventricular pressure (LVP), rate-pressure product, and maximal values of the first derivative of LVP elicited by hrSTA-CgA(1-78) at 33 nM is abolished by blocking G(i/o) proteins with pertussis toxin, scavenging NO with hemoglobin, and blocking NOS activity with N(G)-monomethyl-l-arginine or N(5)-(iminoethyl)-l-ornithine, soluble guanylate cyclase with 1H-[1,2,4]oxadiazole-[4,4-a]quinoxalin-1-one, and protein kinase (PKG) with KT5823. Data suggest the involvement of the G(i/o) proteins/NO-cGMP-PKG pathway in the hrSTA-CgA(1-78)-dependent cardioinhibition. When given before 30 min of ischemia, hrSTA-CgA(1-78) significantly reduced the size of the infarct from 64 +/- 4 to 32 +/- 3% of the left ventricular mass. This protective effect was abolished by either NOS inhibition or PKC blockade and was attenuated, but not suppressed, by the blockade of A(1) receptors. These results suggest that hrSTA-CgA(1-78) activity triggers two different pathways: one of these pathways is mediated by A(1) receptors, and the other is mediated by NO release. As with repeated brief preconditioning ischemia, hrSTA-CgA(1-78) may be considered a stimulus strong enough to trigger both pathways, which may converge on PKC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416598     DOI: 10.1152/ajpheart.01352.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  18 in total

Review 1.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

2.  Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart.

Authors:  Bhawanjit K Brar; Erik Helgeland; Sushil K Mahata; Kuixing Zhang; Daniel T O'Connor; Karen B Helle; Anne K Jonassen
Journal:  Regul Pept       Date:  2010-07-22

3.  The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes.

Authors:  Bruno Tota; Stefano Gentile; Teresa Pasqua; Eleonora Bassino; Hisatsugu Koshimizu; Niamh X Cawley; Maria C Cerra; Y Peng Loh; Tommaso Angelone
Journal:  FASEB J       Date:  2012-03-29       Impact factor: 5.191

Review 4.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology.

Authors:  Karen B Helle; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

5.  Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processing.

Authors:  Nitin Gupta; Steven J Bark; Weiya D Lu; Laurent Taupenot; Daniel T O'Connor; Pavel Pevzner; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

Review 6.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

7.  Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.

Authors:  Maria-Giulia Perrelli; Francesca Tullio; Carmelina Angotti; Maria Carmela Cerra; Tommaso Angelone; Bruno Tota; Giuseppe Alloatti; Claudia Penna; Pasquale Pagliaro
Journal:  Pflugers Arch       Date:  2013-01-15       Impact factor: 3.657

8.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

9.  Serpinins: role in granule biogenesis, inhibition of cell death and cardiac function.

Authors:  Y P Loh; H Koshimizu; N X Cawley; B Tota
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

10.  pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury.

Authors:  T Pasqua; B Tota; C Penna; A Corti; M C Cerra; P Loh Y; T Angelone
Journal:  J Endocrinol       Date:  2015-09-23       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.